Novartis Beats Gleevec Monopolization Suit At 1st Circ.
The First Circuit on Tuesday granted Novartis' bid to dismiss an antitrust suit alleging it used sham litigation to extend a monopoly over the leukemia drug Gleevec, finding that a group...To view the full article, register now.
Already a subscriber? Click here to view full article